P. Paradiso

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
P R Paradiso, Peter R Paradiso, Patricia Paradiso, Peter Paradiso, P. Paradiso, Peter R. Paradiso, P. R. Paradiso
Publication record
82 papers · 4,693 citations · H-index 29

PAPERS

Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy
20243 citationsauthor #5
Parents’ perception of the school nurse’s role
20204 citationsauthor #3
Relevance of HTLV-1 proviral load in asymptomatic and symptomatic patients living in endemic and non-endemic areas of Argentina
201919 citationsauthor #8
Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule.
20181 citationsauthor #4
Pneumococcal conjugate vaccine in adults: Let’s see what happens
20161 citationsauthor #1
Pneumococcal conjugate vaccine use in adults
201617 citationsauthor #7
Short communication: Emergence of novel A/G recombinant HIV-1 strains in Argentina.
20152 citationsauthor #4
Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule.
201319 citationsauthor #13
Distribution of 13-valent pneumococcal conjugate vaccine Streptococcus pneumoniae serotypes in US adults aged ≥50 years with community-acquired pneumonia.
201399 citationsauthor #8
Challenges in estimating efficacy against pneumococcal pneumonia in children.
20120 citationsauthor #2
Pneumococcal Conjugate Vaccine for Adults: A New Paradigm
201278 citationsauthor #1
Advances in pneumococcal disease prevention: 13-valent pneumococcal conjugate vaccine for infants and children.
201171 citationsauthor #1
High HTLV-I proviral load in patients with HAM/TSP and ATLL but not with other disorders
20110 citationsauthor #6
Advances in pneumococcal vaccines: the 13-valent pneumococcal conjugate vaccine received market authorization in Europe
201063 citationsauthor #2
Essential criteria for evaluation of pneumococcal conjugate vaccine candidates.
200920 citationsauthor #1
Immunology of combining CRM(197) conjugates for Streptococcus pneumoniae, Neisseria meningitis and Haemophilus influenzae in Chilean infants.
200912 citationsauthor #6
Comment on "Serotypes and susceptibility of Streptococcus pneumoniae strains isolated from children in Mexico".
20096 citationsauthor #4
New Vaccines with Global Impact: The Issue of Access
20080 citationsauthor #1
Composition of a multivalent conjugate pneumococcal polysaccharide-protein
20070 citationsauthor #3
P1048 Pandemicfiu preparedness - role of antibiotics
20070 citationsauthor #3
multivalent composition conjugates of pneumococcal polysaccharide-protein
20070 citationsauthor #3
P49 BRCA1 and BRCA2 polymorphisms and intronic variants: whichpathological role?
20070 citationsauthor #8
Estimating the protective concentration of anti-pneumococcal capsular polysaccharide antibodies.
2007355 citationsauthor #9
Establishing government-operated vaccine programs: an industry perspective.
20060 citationsauthor #1
conjugate polysaccharide-protein composition pneumococcal multivante
20060 citationsauthor #2
Multivalent pneumococcal saccharide-protein conjugate composition
20060 citationsauthor #3
Interprotein disulfide bonding between F and G glycoproteins of human respiratory syncytial virus
20057 citationsauthor #3
Evidence that the fusion protein of respiratory syncytial virus exists as a dimer in its native form
20051 citationsauthor #3
Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee.
200360 citationsauthor #13
Recent progress in the development of vaccines for infants and children.
20035 citationsauthor #2
Geographical differences in invasive pneumococcal disease rates and serotype frequency in young children.
2001232 citationsauthor #3
Maternal immunization: the influence of liability issues on vaccine development.
200116 citationsauthor #1
Safety and immunogenicity of four doses of Neisseria meningitidis group C vaccine conjugated to CRM197 in United States infants.
200154 citationsauthor #11
Geographical differences for pneumococcal disease
20010 citationsauthor #3
Which pneumococcal serogroups cause the most invasive disease: implications for conjugate vaccine formulation and use, part I.
2000872 citationsauthor #3
The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use, part II.
2000354 citationsauthor #4
Conjugate Vaccines for Streptococcus pneumoniae
19990 citationsauthor #1
Safety and immunogenicity of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
1999281 citationsauthor #8
Pediatric Combination Vaccines
19990 citationsauthor #1
Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States Infants
1998281 citationsauthor #8
Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia.
1998131 citationsauthor #4
The future of polio immunization in the United States: are we ready for change?
199612 citationsauthor #1
Glycoconjugate vaccines: future combinations.
199616 citationsauthor #1
The immunogenicity of Haemophilus influenzae type b conjugate (HbOC) vaccine in human immunodeficiency virus‐infected and uninfected infants
199528 citationsauthor #6
Combination Vaccines for Diphtheria, Tetanus, Pertussis, and Haemophilus influenzae Type b
199511 citationsauthor #1
Safety and efficacy of diphtheria-tetanus toxoids-pertussis-Haemophilus influenzae type b combination vaccine.
19950 citationsauthor #2
Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.
199490 citationsauthor #1
Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement.
199438 citationsauthor #5
Immunogenicity and safety of respiratory syncytial virus subunit vaccine in seropositive children 18-36 months old.
1993123 citationsauthor #6
Kombinationsvaccin against barnsjukdomar with oekad immunogenicitet hos Varje vaccinkomponent
19930 citationsauthor #1
Immunogen-induced enhanced pulmonary histopathology in the RSV cotton rat model.
19935 citationsauthor #5
Expression of the G glycoprotein gene of human respiratory syncytial virus in Salmonella typhimurium.
199325 citationsauthor #7
Pediatric combination vaccines with enhanced immunogenicity of each vaccine component
19932 citationsauthor #1
Lack of detectable enhanced pulmonary histopathology in cotton rats immunized with purified F glycoprotein of respiratory syncytial virus (RSV) when challenged at 3-6 months after immunization.
199321 citationsauthor #5
Safety and immunogenicity of a combined diphtheria, tetanus, pertussis and Haemophilus influenzae type b vaccine in young infants.
199369 citationsauthor #1
Combined childhood immunizations.
19923 citationsauthor #1
Expression of the F glycoprotein gene from human respiratory syncytial virus in Escherichia coli: mapping of a fusion inhibiting epitope.
199125 citationsauthor #8
Mapping of a fusion related epitope of the respiratory syncytial virus fusion protein.
199111 citationsauthor #1
Vaccin innehaollande protein fraon classic d-1 yttermembranen of meningokocker.
19910 citationsauthor #2
Procedure for Preparing a Vaccine against the Neisseria meningitidis Bacteria and Neisseria meningitidis Strain
19910 citationsauthor #2
Effect of passive antibody on the immune response of cotton rats to purified F and G glycoproteins of respiratory syncytial virus (RSV).
199132 citationsauthor #5
Parvovirus replication in normal and transformed human cells correlates with the nuclear translocation of the early protein NS1
198923 citationsauthor #2
Parvovirus Replication inNormalandTransformed HumanCells Correlates withtheNuclear Translocation oftheEarlyProtein NS1
19890 citationsauthor #2
Comparison of antigenic sites of subtype-specific respiratory syncytial virus attachment proteins.
198950 citationsauthor #6
Fatty acid acylation of the fusion glycoprotein of human respiratory syncytial virus.
198941 citationsauthor #5
Alkaline Phosphatase Fusions to the Respiratory Syncytial Virus F Protein as an Approach to Analyze Its Membrane Topology
19894 citationsauthor #6
Immunization of cotton rats with the fusion (F) and large (G) glycoproteins of respiratory syncytial virus (RSV) protects against RSV challenge without potentiating RSV disease.
1989110 citationsauthor #3
Antigenic structure of the fusion glycoprotein of respiratory syncytial virus.
19893 citationsauthor #1
Respiratory syncytial virus; Vaccines and diagnostic tests
19880 citationsauthor #1
Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus.
1987374 citationsauthor #3
CORRELATION BETWEEN RESPIRATORY SYNCYTIAL VIRUS (RSV) GLYCOPROTEIN SPECIFIC MATERNAL ANTIBODIES AND RSV DISEASE OF INFANTS
19871 citationsauthor #3
Mapping of the amino terminus of the H-1 parvovirus major capsid protein
198447 citationsauthor #1
Identification of multiple forms of the noncapsid parvovirus protein NCVP1 in H-1 parvovirus-infected cells
198445 citationsauthor #1
Correlation between distribution of cytoskeletal proteins and release of alkaline phosphatase-rich vesicles by epiphyseal chondrocytes in primary culture.
198312 citationsauthor #4
Analysis of the protein-protein interactions in the parvovirus H-1 capsid
198320 citationsauthor #1
Canine parvovirus: a biochemical and ultrastructural characterization.
198271 citationsauthor #1
Photochemical cross-linking of the gene 5 protein.fd DNA complex from fd-infected cells.
198233 citationsauthor #1
A transmembrane relationship between fibronectin and vinculin (130 kd protein): serum modulation in normal and transformed hamster fibroblasts.
1981153 citationsauthor #2
Infectious process of the parvovirus H-1: correlation of protein content, particle density, and viral infectivity
198173 citationsauthor #1
Photochemical cross-linking of protein . nucleic acid complexes. The attachment of the fd gene 5 protein to fd DNA.
197931 citationsauthor #1
PHOTO-INDUCED CROSS-LINKING OF GENE 5 PROTEIN TO DNA
19782 citationsauthor #1
Safety and immunogenicity of heptavalent pneumococcal CRM 197 conjugate vaccine in infants and toddlers
year unknown24 citationsauthor #8

TIMELINE

1978 2 citations

1979 31 citations

1981 226 citations

1982 104 citations

1983 32 citations

1984 92 citations

1987 375 citations

1988 0 citations

1989 231 citations

1991 68 citations

1992 3 citations

1993 245 citations

1994 128 citations

1995 39 citations

1996 28 citations

1998 412 citations

1999 281 citations

2000 1,226 citations

2001 302 citations

2003 65 citations

2005 8 citations

2006 0 citations

2007 355 citations

2008 0 citations

2009 38 citations

2010 63 citations

2011 71 citations

2012 78 citations

2013 118 citations

2015 2 citations

2016 18 citations

2018 1 citations

2019 19 citations

2020 4 citations

2024 3 citations

Unknown 24 citations

P. Paradiso

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT